Company intelligence / Profile preview
PostEra
- Ownership
- Private
- Employees
- ~40
- Development stage
- Preclinical
Overview
PostEra leverages its proprietary Proton AI/ML platform to accelerate the design, synthesis, and optimization of small molecule drug candidates. The company has demonstrated rapid progress in both wholly owned preclinical programs—primarily in women’s health/fertility—and through high-profile co-discovery partnerships with major pharmaceutical companies such as Pfizer and Amgen. It played a leading role in the COVID Moonshot initiative. No clinical-stage results have been published as of May 2025.
- Therapeutic areas
- OtherInfectious DiseasesWomen's Health
- Modalities
- Small molecules
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on PostEra.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PostEra.